Accelerate Diagnostics Inc (AXDX) 銘柄情報

AXDX..............................https://stockcharts.com/h-sc/ui?s=AXDX&p=W&b=5&g=0&id=p86431144783

AXDX new 52 lo

New 52 week low lmao

AXDX 10Q due March 5

AXDX new 52 week low

AXDX new 52 week low

AXDX new 52 week low

Accelerate Diagnostics Reports Second Quarter 2022 Financial Results
Published: Aug 15, 2022


TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ --Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.
https://www.biospace.com/article/releases/accelerate-diagnostics-reports-second-quarter-2022-financial-results/

BD, Accelerate Diagnostics Announce Global Commercial Collaboration
BD will offer Accelerate Diagnostic’s rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
NEWS PROVIDED BY

BD (Becton, Dickinson and Company)
Aug 15, 2022, 06:50 ET

SHARE THIS ARTICLE

Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide

FRANKLIN LAKES, N.J. and TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.

Under the agreement, BD will market and sell the Accelerate Pheno® system and Accelerate Arc™ module and associated test kits through its global sales network in territories where products have regulatory approval or registration. These solutions complement BD's existing Clinical Microbiology portfolio and advance the shared goal of both companies to address the global threat of antimicrobial resistance.

"When a patient is very sick, every minute matters," said Brooke Story, president of Integrated Diagnostic Solutions for BD. "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one. Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance."

The Accelerate PhenoTest® BC kit is the first test cleared by the U.S. Food and Drug Administration that can deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures. Recent external studies indicate this solution offers results one to two days faster than traditional laboratory methods, which can include culturing samples for 18 to 24 hours, and then performing a susceptibility test that can take eight to 24 hours to result. This enables clinicians to optimize antibiotic selection and dosage specific to the individual patient, days earlier. It is well established in peer-reviewed literature that improving time to optimal therapy benefits both patient outcomes and hospital operations.

The Accelerate Arc™ module is a simple load-and-go system that eliminates the requirement of a subculture for MALDI ID as well as the need for lengthy hands-on time by automating the direct MALDI ID workflow. It is currently US , CE-IVDR and UKCA registered for positive blood cultures.

"With BD's large installed customer base of clinical microbiology systems, this collaboration exponentially increases our global commercial reach and provides numerous ways to increase our market penetration with Pheno and Arc to reach more clinicians and patients," said Jack Phillips, president and CEO of Accelerate Diagnostics. "Beyond the immediate clinical and commercial benefits, we are excited about the opportunity to collaborate with BD as a long-term leader in clinical microbiology."

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistant infections, a leading cause of sepsis. The company's first fully automated platform to provide rapid identification and antimicrobial susceptibility results remains the only solution currently cleared for use with positive blood culture samples by the U.S. FDA.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately

Insider bought one million shares yesterday.

$AXDX - Short Squeeze Play

$AXDX: Sudden surger here...... now 6.25


BOoooooooooooommmmmmmmmmmmmmmmmmmm




WASSUPPPPPPPPPPPPPPP



GO $AXDX

$AXDX volume just kicked in big time.

Looks like the squeeze opportunity is circulating. Everyone wants the next $GME and we know we may have it ! :)

25% GAIN EASY HERE $10.74

It’s going over $30
Today

$25 target for me

Buy and Hold

Added more today

I've started building a position this week. Little bits at a time spread out every few days while this downtrend continues.

Upside greater probability than downside with next new release, IMO

$AXDX got EUA COVID antibody approval tonight!

* * $AXDX Video Chart 03-23-2020 * *

Link to Video - click here to watch the technical chart video

News: $AXDX Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

TUCSON, Ariz. , Oct. 3, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that were first reported in the Company's September 18, ...

Find out more AXDX - Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

News: $AXDX Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

TUCSON, Ariz. , Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. "We are thrilled with...

In case you are interested AXDX - Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

Clinicaltrials.gov listing of the RAPIDS-GN study show subjects should be enrolling this month. Will be excited to see the results.
Anyone else concerned that the study will be done ONLY on samples that are already positive by blood culture? Is this smart study design, or stacking the deck? Is there really that much to be gained in using the device after the time has passed and generated a positive blood culture?

https://seekingalpha.com/news/3290400-takeover-rumor-du-jour-accelerate-diagnostics-smiths-group

Just listened Q1 Conference Call. All sounds great, all on track. will be a great 2017. Looking for analysts to come out with new Price Targets now.

AXDX insider purchases recorded yesterday by Schuler Jack W, patience John, Strobeck Matthew purchasing a total of 400.068 shares at a price of $19.00

fast and steady profit scan AXDX bullish 27.26



normal chart


log chart

AXDX bullish 22.05

Harry has posted Charts of the Day video on AXDX at TheTechTrader site noting:Accelerate Diagnostics, Inc. (AXDX) has really be acting well. After a 3-wave, corrective pullback, and a nice base, it popped and went right up to the declining topsline and backed off. It was actually down 59 cents to 16.28 on Thursday. I put a swing on it. I’m looking for it to ideally hold a pullback around 15 1/2, 19, and eventually 23-24.

AXDX - duh... The price is dropping because the company issued more shares in a dilutive manner... And bogus lawsuits have been filed to coordinate with a concerted effort by Spanos and the likes to short this stock for huge profits... Duh subsequently lawsuits are thrown out by courts... Blah blah blah all part of the game with pre revenue biotech companies... LOL... Product with reach market by June of 2016... Because of recent dilution... Would not surprise me if PPS reaches 50% of price at dilution which was say $17.5 at time... So reasonable buy in price of $8.75 may be achievable... But happy to buy in anywhere below a dime... Just saying!!!!

$AXDX recent news/filings

bullish 21.43
rallying off a base
high volume
crossing moving averages up

## source: finance.yahoo.com

Thu, 10 Dec 2015 18:06:45 GMT ~ These 4 Stocks Have Investors Scrambling for the Exits Today


read full: http://www.insidermonkey.com/blog/these-4-stocks-have-investors-scrambling-for-the-exits-today-401765/
*********************************************************

Thu, 10 Dec 2015 08:54:00 GMT ~ 3:54 am Accelerate Diagnostics prices 5,588,236 shares of common stock at $17.00 per share


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#axdx
*********************************************************

Thu, 10 Dec 2015 04:21:42 GMT ~ Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock

[at noodls] - 93bda79b-2008-4908-99b8-121314b7d993 December 9, 2015 TUCSON, Ariz., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering ...

read full: http://www.noodls.com/view/608DB98EBE937D8C2B7F05517AE73FF189CE2300
*********************************************************

Thu, 10 Dec 2015 03:46:49 GMT ~ Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock

[GlobeNewswire] - TUCSON, Ariz. -- Accelerate Diagnostics, Inc. today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of ...

read full: http://finance.yahoo.com/news/accelerate-diagnostics-announces-pricing-public-034649687.html
*********************************************************

Wed, 09 Dec 2015 11:06:37 GMT ~ ACCELERATE DIAGNOSTICS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151209/axdx8-k.html
*********************************************************

$AXDX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$AXDX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AXDX/company-info
Ticker: $AXDX
OTC Market Place: Not Available
CIK code: 0000727207
Company name: Accelerate Diagnostics, Inc.
Company website: http://www.accelr8.com
Incorporated In: DE, USA

$AXDX share structure

## source: otcmarkets.com

Market Value: $958,755,827 a/o Dec 11, 2015
Shares Outstanding: 44,738,956 a/o Oct 26, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$AXDX extra dd links

Company name: Accelerate Diagnostics, Inc.
Company website: http://www.accelr8.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AXDX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AXDX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AXDX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/news - http://finance.yahoo.com/q/h?s=AXDX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AXDX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AXDX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AXDX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accelerate+Diagnostics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accelerate+Diagnostics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accelerate+Diagnostics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.accelr8.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.accelr8.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.accelr8.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AXDX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000727207&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AXDX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AXDX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AXDX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AXDX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AXDX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AXDX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AXDX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AXDX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AXDX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AXDX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AXDX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AXDX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AXDX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AXDX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AXDX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AXDX



$AXDX DD Notes ~ http://www.ddnotesmaker.com/AXDX

AXDX

$AXDX recent news/filings

bullish

## source: finance.yahoo.com

Sat, 16 May 2015 19:57:02 GMT ~ Rosen Law Firm Reminds Accelerate Diagnostics, Inc. Investors of the Important May 18, 2015 Deadline In the Class Action Filed by the Firm - AXDX

[GlobeNewswire] - NEW YORK -- The Rosen Law Firm, P.A., a global investor rights law firm, reminds purchasers of Accelerate Diagnostics, Inc. securities from March 7, 2014 through February 17, 2015 of the important May ...

read full: http://finance.yahoo.com/news/rosen-law-firm-reminds-accelerate-195702018.html
*********************************************************

Fri, 15 May 2015 17:04:12 GMT ~ ACCELERATE DIAGNOSTICS, INC Financials


read full: http://finance.yahoo.com/q/is?s=axdx
*********************************************************

Thu, 14 May 2015 17:07:18 GMT ~ ACCELERATE DIAGNOSTICS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150514/axdx8-k.html
*********************************************************

Wed, 13 May 2015 21:33:22 GMT ~ DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Accelerate Diagnostics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – AXDX

[GlobeNewswire] - STEVENSON, Md., May 13, 2015-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...

read full: http://finance.yahoo.com/news/deadline-alert-brower-piven-encourages-213322994.html
*********************************************************

Wed, 13 May 2015 16:00:18 GMT ~ SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Accelerate Diagnostics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 18, 2015 -- AXDX

[GlobeNewswire] - NEW YORK -- The following statement is being issued by Levi & Korsinsky, LLP:

read full: http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-160018396.html
*********************************************************

$AXDX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$AXDX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AXDX/company-info
Ticker: $AXDX
OTC Market Place: Not Available
CIK code: 0000727207
Company name: Accelerate Diagnostics, Inc.
Company website: http://www.accelr8.com
Incorporated In: CO, USA


$AXDX share structure

## source: otcmarkets.com

Market Value: $1,157,071,394 a/o Jun 04, 2015
Shares Outstanding: 44,657,329 a/o Apr 21, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$AXDX extra dd links

Company name: Accelerate Diagnostics, Inc.
Company website: http://www.accelr8.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AXDX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AXDX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AXDX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/news - http://finance.yahoo.com/q/h?s=AXDX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AXDX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AXDX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AXDX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accelerate+Diagnostics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accelerate+Diagnostics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accelerate+Diagnostics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.accelr8.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.accelr8.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.accelr8.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AXDX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000727207&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AXDX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AXDX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AXDX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AXDX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AXDX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AXDX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AXDX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AXDX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AXDX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AXDX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AXDX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AXDX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AXDX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AXDX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AXDX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AXDX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AXDX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AXDX



$AXDX DD Notes ~ http://www.ddnotesmaker.com/AXDX

AXDX - I would expect some PPS reduction... AXDX would want to be squarely under $1B market cap on May 30/31st... if AXDX is under $1B market cap on that day... it will be added back to the Russell 2000/3000 indexes... that drives a bit of demand as indexes have to load shares of all new members during the rebalancing process...

Remember AXDX is likely to move from development stage bio-device company to full on bio-device company with a "razor / razor-blade" product model in April/June of 2016... could be a nice play over 12 months... historically it will go through at least one or two more SHORT troughs between now and then... but an awesome timing play or buy and hold play...

GO AXDX!!!

Quiet here since Andrew issued his report. Still $22 not $1 hahah to say the least.

Seems like all these "me too" law firms piling on is a sign of real desperation. Probably some short covering going on currently? Every new announcement is followed by a bump in stock price. They are wasting their time; the price has recovered from its original price when these shorting articles came out.

AXDX - Citron Research is run by Andrew Edward Left (born July 9, 1970 in Detroit Michigan) is an activist short seller, author and editor of the online investment newsletter Citron Research, formerly StockLemon.com...

This is a major attempt to discredit a very reputable bio venture management team that has taken over AXDX... there is absolutely nothing to the research provided by Citron Research... they have no biotechnology expertise to draw from... the recent SEC correspondence DID NOT shine any new light on the ID/AST technology underdevelopment... there has been no "exposure of fraud"... the technology works as described... and will be a "game changing" technology that will meet vast acceptance once clinical testing is complete and FDA approval is met...

The shareholder lawsuits but the ambulance chasing law firms... is only part of the SHORT selling strategy...

Despite all of this noise... AXDX continues to get significant government grant funding from NIH... and its collaborative partners include the prestigious Washington University School of Medicine in St. Louis...

This is a development stage biotechnology firm... there are little if any revenues... it is well capitalized... and well managed... the technology continues to demonstrate significant reduction in time of identification of multi-drug resistant bacteria... the technology has just received ISA 13485:2003 certifications on its initial installation... and continued expansion of its partner utilization network is occurring at present to gather more testing feedback on the device and technologies applications...

You might very well utilize this very well coordinated SHORT SCARE to find a great entry point for a company that will see PPS between $45 to $70 by mid to late 2016... when the product (which is a razor / razor blade product model)... is fully being marketed with a potential market of every hospital and micro/molecular laboratory in North America... then Europe... then Asia... then everywhere else...

GO AXDX!!!

ACCELERATE SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Accelerate Diagnostics, Inc.


http://www.businesswire.com/news/home/20150313005824/en/ACCELERATE-SHAREHOLDER-ALERT-Shareholder-Rights-Law-Firm#.VQble2Zl-zA

AXDX - Read the SEC communications related to AXDX filings... as a CFO... whose wife is a Molecular Biologist PhD / MD (Pathology)... I don't see anything concerning... It all looks consistent to the information I used to buy the stock initially 4 to 5 years ago... except the current board and management team are much improved over the prior iteration... I think this Rosen law firm is the SEC registrant equivalent to an "ambulance chaser"... there has been no deception... and the technology is relevant and will be well received... I believe the articles and the legal filings are all part of a concerted SHORT selling campaign... meanwhile AXDX continues progressing on the development of the ID/AST technology platform... relevant FDA testing will occur and in April to June of 2016... this stock will soar like it has not before to a reasonable target range of $45 to $70 PPS... that said as a pre-revenue development stage bio technology firm this concerted SHORT campaign might drive the PPS down to 14's or 15's in the next 30 days... here is a hint!!! AXDX will be re-added to the Russell 2000 index in June... this will create significant demand for the stock... and PPS will likely fully rebound and go over $30 PPS as it has now on three separate occasions... let this SHORT campaign get us a lower buy in point for a 90 - 120 day short term profit taking exercise... or a buy in point for a LONG hold exercise...

Research this executive management team... and the members of the board of directors... this is a group that consistently takes bio start ups to the top... with no black marks against their reputations...

GO AXDX!!!

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Accelerate Diagnostics - AXDX

http://www.businesswire.com/news/home/20150311006279/en/EQUITY-ALERT-Rosen-Law-Firm-Announces-Investigation#.VQL7YWZl-zA

AXDX - Citron is just as bogus as the Seeking Alpha... please do SHORT the stock... I need a good entry point in the 15s... It appears that all these SHORT writers focus on stuff from 5 or 10 years ago... LOL The venture group that took over AXDX has a track record of integrity and HUGE success... Jack Shuler... John Patience (Ventana Medical Systems & Stericycle are just two multi-billion dollar firms they have been instrumental in leading)... Lawrence Mehren is an experienced leading in the life science's space...

This is a startup life science technology firm... with no real product on the market and thus no revenues... AXDX would like to be added back to the Russell 2000 index a mid 2015... the market cap needs to retreat well back from the $1B range... would be target around $500M-600M range... that would allow these SHORTs to make a very nice profit... and get AXDX back on to the Russell 2000 Index... that creates demand to fill the index funds / portfolio holdings... and will drive PPS back up to over $30PPS...

These "hack" articles don't actually know any science... and investors have been treated more than fairly since the new management took over... and the science is real... with significant NIH grant funding... to prove its potential viability... AXDX is a fun roller coaster as it is a pre-revenue company... the volatility introduced by these SHORT hacks gives me the opportunity to BUY LOW and SELL HIGH multiple times...

I will say this... I will BUY LOW toward the end of 2015 (after another SHORT hack)... and become very LONG on AXDX at that time... I feel this stock will go to $45 to $70 PPS in mid to late 2016 once the product is introduced... Molecular biology laboratories of every hospital will be placing orders for this innovative life saving technology.... and each hospital's Chief Legal Officer will require the device as well...

Let the SHORT hacks get us a very nice buy in point... and we can say thanks by end of June!!!

GO AXDX!!!

Yes, by all means, please do short; be certain you have the funds to cover when this stock wakes up. I understand that the market cap seems very high for a company with no revenues, but for what they are doing and the efficacy of the product, it is entirely warranted.

This Citron article is totally bogus. The company's dialogue with the SEC had nothing to do with being "exposed" or trying to confuse the FDA and all to do with educating them to this new, complex technology; that is the reason that blood culture bottles were used in the initial filing, to facilitate the quickest path to approval.

Neither Novartis or BD was capable of taking on the engineering development: Novartis closed their infectious Disease division and BD acquired a highly automated culture process layout from Europe. They were never interested in abandoning the status quo of two to four day cycle times for culture results.

Consider the ownership, management and money behind this project; these guys are very heavy hitters, the real deal, not beginners or hustlers as the recent grossly misguided articles indicate.

Actually, the greater the short, the grater the advantage to longs in the end. So, thank you in advance, for your support.

Citron Research EXPOSED AXDX as a "Big Lie Exposed by SEC — $1.00 Target within 18 Months" read the research here citronresearch.com/ I shorted Short this stock

AXDX - mmillionaire - Yes, I concur. My wife is an MD/PhD Pathologist / Molecular Biologists... she has confirmed the technology and practical application... as have other credentialed medical folks such as those at Denver Health, Washington University in St. Louis, and NIH...

The venture group behind AXDX has successfully taken start up stage bio tech companies Stericycle and Ventana to multi-billion dollar public companies...

Let the SHORTS play games... and create nice buy in points... this is a real company, with real game changing medical technology, with proven venture guys running the show... in mid 2016 this company will make a lot of shareholder very happy wealthy and seem wise...

GO AXDX!!!

This is what I learned by speaking with other AXDX shareholders who are knowledgeable about the science behind the company.
There are no competitor or comparisons in other 10K's because no one besides AXDX does BOTH rapid ID (molecular and phenotype) and AST (antibiotic susceptibility testing), which is the future "standard of care".
The current blood culturing technologies including all the FAST molecular tests by Cephaid, BD, Abbott and BioMuerio all KILL the bugs during ID. AXDX is the only test that keeps the bugs alive for AST testing. This is important because empiric therapy the current "standard of care" is wrong 37% of the time in determining the correct antibiotic drug to give the patient. The author of the misleading article touted Abbott Labs as having an edge in the area of rapid diagnosis. The largest shareholder of AXDX is former president of Abbot! Another criticism by the author of this article is the manner in which AXDX is doing initial testing. The reason AXDX is doing initial testing on blood culture bottles is that it is the fastest way to get FDA approval. Apparently the writer(s) of this article are clueless about this science.
For these reasons and many more, the National Institute of Health chose AXDX to receive a $5 million grant to study the antibiotic resistant SUPERBUG.

AXDX - I think the author of the trashing article is scum... Do you think the National Institute of Health would give a $5M grant to Accelerate if they were doing anything wrong as the author implies... Just a SHORT lying liar... LOL


Link to GREAT News!!! - http://www.prnewswire.com/news-releases/denver-health-medical-center-and-accelerate-diagnostics-awarded-5-million-grant-to-study-antibiotic-resistant-super-bug-300039240.html

GO AXDX!!!

To be clear, by "these people" I mean the people that wrote the misleading article.

Lodo, have you been in touch with the company concerning this shorting article? All of the bunk prior to Schuler, Mehren and company has been solidly refuted, yes that is public knowledge. What about the new claims of misleading shareholders, misrepresenting the technology and not reporting stock sales - are these grounds for legal action against these people?

AXDX - major SHORT effort on this stock... from a scum short seller on Seeking Alpha... that doesn't do real research or really know anything about science... just looks for a development stage company with no revenues and high market value... and writes his gutter opinions to drive PPS down for profits as a SHORT... notice in the attached drivel (article)... he actually discloses he is SHORT on AXDX... most of the newsworthy crap in the drivel is bogus and significantly out of date... and not sure he knows science or even how to spell science for that matter... but it is going to drive PPS down... as AXDX is a good target for a concerted SHORT Selling campaign... additionally it might be good for AXDX to have its market cap go down... AXDX was moved out of the Russell 2000 index last June as its market value went over $1B... it would be good for AXDX to rejoin Russell 2000 index in June... but its market cap needs to be significantly below $1B to do so...

I would look to buy in at or around 14 or 15's...

When AXDX released its Accelerate ID/AST system to the market... every hospital in North America with an ICU, CCU or significant surgery operations will add one to its Molecular Laboratory in Pathology... to not do so would lead to multi million dollar lawsuits... the science works... the price point will be tolerable... and its a razor / razor blade model... lots of profits... great biotech venture firm behind this company... the product will reach market in late Spring or Summer 2016... at that point the PPS could reach 40 to 70 dollars per share...

Let the SHORT scum do what they do...

Buy this at the coming lows in the 14s and 15s... and hold for 18 months...

Here is the link promised... http://seekingalpha.com/article/2926786-accelerate-diagnostics-a-misleading-story-ripe-for-decline

GO AXDX!!! Solve drug resistant infections, save lives and make us money in 2016!!!